Non-sirtuin histone deacetylases in the control of cardiac aging

Journal of Molecular and Cellular Cardiology

Volumn 83, Issue , 2015, Pages 14-20

  Ferguson, Bradley S ^a   McKinsey, Timothy A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Aging; Heart failure; Histone deacetylase

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1C; ENTINOSTAT; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 10; HISTONE DEACETYLASE 11; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; MANGANESE SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MOCETINOSTAT; PROTEIN KINASE D; PROTEIN P15; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; TUBASTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; HISTONE; ISOENZYME;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA CONSTRICTION; ATRIAL FIBRILLATION; AUTOPHAGY; CARDIOMYOPATHY; DISEASE COURSE; DRUG EFFICACY; DUSP5 GENE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; IN VIVO STUDY; INFLAMMATION; ISCHEMIC CARDIOMYOPATHY; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; UPREGULATION; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE; CARDIOMEGALY; CLASSIFICATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

MAMMALIA;

AGING; ANIMALS; CARDIOMEGALY; HEART FAILURE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; INFLAMMATION; ISOENZYMES; MYOCARDIUM; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84937966754     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.03.010     Document Type: Review

References (80)

1. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C., et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840.
2. Lundby A., Lage K., Weinert B.T., Bekker-Jensen D.B., Secher A., Skovgaard T., et al. Proteomic analysis of lysine acetylation sites in rat tissues reveals organ specificity and subcellular patterns. Cell Rep 2012, 2:419-431.
3. Gregoretti I.V., Lee Y.M., Goodson H.V. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004, 338:17-31.
4. Berry J.M., Cao D.J., Rothermel B.A., Hill J.A. Histone deacetylase inhibition in the treatment of heart disease. Expert Opin Drug Saf 2008, 7:53-67.
5. McKinsey T.A. Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 2012, 52:303-319.
6. Cao D.J., Wang Z.V., Battiprolu P.K., Jiang N., Morales C.R., Kong Y., et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A 2011, 108:4123-4128.
7. Kee H.J., Sohn I.S., Nam K.I., Park J.E., Qian Y.R., Yin Z., et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113:51-59.
8. Xie M., Kong Y., Tan W., May H., Battiprolu P.K., Pedrozo Z., et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation 2014, 129:1139-1151.
9. Przyklenk K., Dong Y., Undyala V.V., Whittaker P. Autophagy as a therapeutic target for ischaemia/reperfusion injury? Concepts, controversies, and challenges. Cardiovasc Res 2012, 94:197-205.
10. Aune S.E., Herr D.J., Mani S.K., Menick D.R. Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion. J Mol Cell Cardiol 2014, 72:138-145.
11. Schuetze K.B., McKinsey T.A., Long C.S. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol 2014, 70:100-107.
12. Williams S.M., Golden-Mason L., Ferguson B.S., Schuetze K.B., Cavasin M.A., Demos-Davies K., et al. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 2014, 67:112-125.
13. Nural-Guvener H.F., Zakharova L., Nimlos J., Popovic S., Mastroeni D., Gaballa M.A. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis Tissue Repair 2014, 7:10.
14. Blakeslee W.W., Wysoczynski C.L., Fritz K.S., Nyborg J.K., Churchill M.E., McKinsey T.A. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Cell Signal 2014, 26:2912-2920.
15. Vejpongsa P., Yeh E.T. Wrestling with heart failure: SUMO-1 to the rescue. Circ Res 2014, 114:1561-1563.
16. Lishnevsky M., Haudek S.B. Epigenetic regulation of fibrocyte differentiation?. J Mol Cell Cardiol 2014, 69:85-87.
17. Herzog E.L., Bucala R. Fibrocytes in health and disease. Exp Hematol 2010, 38:548-556.
18. Cieslik K.A., Taffet G.E., Carlson S., Hermosillo J., Trial J., Entman M.L. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol 2011, 50:248-256.
19. Cunliffe V.T. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev 2008, 18:404-410.
20. Kelly R.D., Cowley S.M. The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 2013, 41:741-749.
21. Longworth M.S., Laimins L.A. Histone deacetylase 3 localizes to the plasma membrane and is a substrate of Src. Oncogene 2006, 25:4495-4500.
22. Samant S.A., Courson D.S., Sundaresan N.R., Pillai V.B., Tan M., Zhao Y., et al. HDAC3-dependent reversible lysine acetylation of cardiac myosin heavy chain isoforms modulates their enzymatic and motor activity. J Biol Chem 2011, 286:5567-5577.
23. Eom G.H., Kook H. The role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy. BMB Rep 2014, [Epub ahead of print].
24. Eom G.H., Nam Y.S., Oh J.G., Choe N., Min H.K., Yoo E.K., et al. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy. Circ Res 2014, 114:1133-1143.
25. Montgomery R.L., Potthoff M.J., Haberland M., Qi X., Matsuzaki S., Humphries K.M., et al. Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice. J Clin Invest 2008, 118:3588-3597.
26. Sun Z., Singh N., Mullican S.E., Everett L.J., Li L., Yuan L., et al. Diet-induced lethality due to deletion of the HDAC3 gene in heart and skeletal muscle. J Biol Chem 2011, 286:33301-33309.
27. Sharifi-Sanjani M., Shoushtari A.H., Quiroz M., Baust J., Sestito S.F., Mosher M., et al. Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. J Am Heart Assoc 2014, 3:e000670.
28. Sun Z., Feng D., Fang B., Mullican S.E., You S.H., Lim H.W., et al. Deacetylase-independent function of HDAC3 in transcription and metabolism requires nuclear receptor corepressor. Mol Cell 2013, 52:769-782.
29. Ferguson B.S., Harrison B.C., Jeong M.Y., Reid B.G., Wempe M.F., Wagner F.F., et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A 2013, 110:9806-9811.
30. Lorenz K., Schmitt J.P., Schmitteckert E.M., Lohse M.J. A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med 2009, 15:75-83.
31. Ruppert C., Deiss K., Herrmann S., Vidal M., Oezkur M., Gorski A., et al. Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy. Proc Natl Acad Sci U S A 2013, 110:7440-7445.
32. Pillai V.B., Sundaresan N.R., Samant S.A., Wolfgeher D., Trivedi C.M., Gupta M.P. Acetylation of a conserved lysine residue in the ATP binding pocket of p38 augments its kinase activity during hypertrophy of cardiomyocytes. Mol Cell Biol 2011, 31:2349-2363.
33. Zhao T.C., Cheng G., Zhang L.X., Tseng Y.T., Padbury J.F. Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc Res 2007, 76:473-481.
34. Kee H.J., Bae E.H., Park S., Lee K.E., Suh S.H., Kim S.W., et al. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity. Kidney Blood Press Res 2013, 37:229-239.
35. Olson D.E., Udeshi N.D., Wolfson N.A., Pitcairn C.A., Sullivan E.D., Jaffe J.D., et al. An unbiased approach to identify endogenous substrates of "histone" deacetylase 8. ACS Chem Biol 2014, 9:2210-2216.
36. Wolfson N.A., Pitcairn C.A., Fierke C.A. HDAC8 substrates: histones and beyond. Biopolymers 2013, 99:112-126.
37. Waltregny D., Glenisson W., Tran S.L., North B.J., Verdin E., Colige A., et al. Histone deacetylase HDAC8 associates with smooth muscle alpha-actin and is essential for smooth muscle cell contractility. FASEB J 2005, 19:966-968.
38. Karolczak-Bayatti M., Sweeney M., Cheng J., Edey L., Robson S.C., Ulrich S.M., et al. Acetylation of heat shock protein 20 (Hsp20) regulates human myometrial activity. J Biol Chem 2011, 286:34346-34355.
39. Li S., Fossati G., Marchetti C., Modena D., Pozzi P., Reznikov L.L., et al. Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo. J Biol Chem 2014, 290:2368-2378.
40. McKinsey T.A. Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovasc Res 2007, 73:667-677.
41. Jones P., Altamura S., De F.R., Gallinari P., Lahm A., Neddermann P., et al. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg Med Chem Lett 2008, 18:1814-1819.
42. Lahm A., Paolini C., Pallaoro M., Nardi M.C., Jones P., Neddermann P., et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci U S A 2007, 104:17335-17340.
43. Zhang C.L., McKinsey T.A., Olson E.N. Association of class II histone deacetylases with heterochromatin protein 1: potential role for histone methylation in control of muscle differentiation. Mol Cell Biol 2002, 22:7302-7312.
44. Hohl M., Wagner M., Reil J.C., Muller S.A., Tauchnitz M., Zimmer A.M., et al. HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 2013, 123:1359-1370.
45. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 2008, 18:291-297.
46. Zhang D., Wu C.T., Qi X., Meijering R.A., Hoogstra-Berends F., Tadevosyan A., et al. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of alpha-tubulin proteostasis in experimental and human atrial fibrillation. Circulation 2014, 129:346-358.
47. Lemon D.D., Horn T.R., Cavasin M.A., Jeong M.Y., Haubold K.W., Long C.S., et al. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol 2011, 51:41-50.
48. Butler K.V., Kalin J., Brochier C., Vistoli G., Langley B., Kozikowski A.P. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010, 132:10842-10846.
49. Demos-Davies K.M., Ferguson B.S., Cavasin M.A., Mahaffey J.H., Williams S.M., Spiltoir J.I., et al. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol 2014, 307:H252-H258.
50. McLendon P.M., Ferguson B.S., Osinska H., Bhuiyan M.S., James J., McKinsey T.A., et al. Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proc Natl Acad Sci U S A 2014, 111:E5178-E5186.
51. De Meyer G.R., De Keulenaer G.W., Martinet W. Role of autophagy in heart failure associated with aging. Heart Fail Rev 2010, 15:423-430.
52. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010, 6:238-243.
53. Sharma K., Kass D.A. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 2014, 115:79-96.
54. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
55. Scantlebury D.C., Borlaug B.A. Why are women more likely than men to develop heart failure with preserved ejection fraction?. Curr Opin Cardiol 2011, 26:562-568.
56. Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269.
57. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
58. Pitt B., Pfeffer M.A., Assmann S.F., Boineau R., Anand I.S., Claggett B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014, 370:1383-1392.
59. Shah S.J., Gheorghiade M. Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 2008, 300:431-433.
60. Dai D.F., Rabinovitch P.S. Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc Med 2009, 19:213-220.
61. Franceschi C., Bonafe M., Valensin S., Olivieri F., De L.M., Ottaviani E., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.
62. Judge S., Jang Y.M., Smith A., Hagen T., Leeuwenburgh C. Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of aging. FASEB J 2005, 19:419-421.
63. Wu J., Xia S., Kalionis B., Wan W., Sun T. The role of oxidative stress and inflammation in cardiovascular aging. Biomed Res Int 2014, 2014:615312.
64. McKinsey T.A. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med 2011, 17:434-441.
65. Cardinale J.P., Sriramula S., Pariaut R., Guggilam A., Mariappan N., Elks C.M., et al. HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension 2010, 56:437-444.
66. Fass D.M., Shah R., Ghosh B., Hennig K., Norton S., Zhao W.N., et al. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett 2010, 2:39-42.
67. Wang M., Zhang J., Walker S.J., Dworakowski R., Lakatta E.G., Shah A.M. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol 2010, 48:765-772.
68. Das K.C., Muniyappa H. Age-dependent mitochondrial energy dynamics in the mice heart: role of superoxide dismutase-2. Exp Gerontol 2013, 48:947-959.
69. Dai D.F., Santana L.F., Vermulst M., Tomazela D.M., Emond M.J., MacCoss M.J., et al. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 2009, 119:2789-2797.
70. Treuting P.M., Linford N.J., Knoblaugh S.E., Emond M.J., Morton J.F., Martin G.M., et al. Reduction of age-associated pathology in old mice by overexpression of catalase in mitochondria. J Gerontol A Biol Sci Med Sci 2008, 63:813-822.
71. Parmigiani R.B., Xu W.S., Venta-Perez G., Erdjument-Bromage H., Yaneva M., Tempst P., et al. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A 2008, 105:9633-9638.
72. Wang B., Rao Y.H., Inoue M., Hao R., Lai C.H., Chen D., et al. Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat Commun 2014, 5:3479.
73. de Zoeten E.F., Wang L., Butler K., Beier U.H., Akimova T., Sai H., et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011, 31:2066-2078.
74. Bush E.W., McKinsey T.A. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors. Circ Res 2010, 106:272-284.
75. Loffredo F.S., Nikolova A.P., Pancoast J.R., Lee R.T. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res 2014, 115:97-107.
76. McKinsey T.A. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart. J Mol Cell Cardiol 2011, 51:491-496.
77. Pedram A., Razandi M., Narayanan R., Dalton J.T., McKinsey T.A., Levin E.R. Estrogen regulates histone deacetylases to prevent cardiac hypertrophy. Mol Biol Cell 2013, 24:3805-3818.
78. Fraczek J., Vanhaecke T., Rogiers V. Toxicological and metabolic considerations for histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2013, 9:441-457.
79. LeWinter M.M., Granzier H.L. Cardiac titin and heart disease. J Cardiovasc Pharmacol 2014, 63:207-212.
80. Janczewski A.M., Lakatta E.G. Modulation of sarcoplasmic reticulum Ca(2+) cycling in systolic and diastolic heart failure associated with aging. Heart Fail Rev 2010, 15:431-445.